Nimotuzumab biosimilar (IBC Generium)

尼妥珠单抗生物类似药 (IBC Generium)

Report date: 2022/03/30 10:39:10

Base Information

Drug NameNimotuzumab biosimilar (IBC Generium)
Drug Alias Name尼妥珠单抗生物仿制药 (IBC Generium)尼莫妥珠单抗生物仿制药 (IBC Generium)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar
Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonists
TargetsEpidermal growth factor receptor erbB1
Therapy Area/IndicationsHead and Neck Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesInternational Biotechnology Center Generium Llc
China Registration ClassN/A

Develop Information

Active CompaniesInternational Biotechnology Center Generium Llc
Inactive CompaniesN/A
Active IndicationsHead and Neck Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A